BioSpace News Archive

Drug Development

NEW DATA PRESENTED ON ASLAN’S VARLITINIB AT ESMO SHOW PROMISING RESULTS IN HEAVILY PRE-TREATED BTC AND CRC PATIENTS

ASLAN Pharmaceuticals today announced the presentation of new data from an ongoing phase 1 study to determine the safety, tolerability and maximum tolerated dose (MTD) of varlitinib in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours.

October 29, 2018
·
5 min read
Global pharma set for strong year with record 164 countries and 44,500[1] attendees at CPhI Worldwide

CPhI Worldwide pharma survey shows improving outlook for pharma economies globally, with China and India showing the fastest improvement

October 29, 2018
·
5 min read
Business

GeoVax Announces Publication of HIV Vaccines Review

Comprehensive Review Published in the Peer-Reviewed Journal, Clinical Pharmacology and Therapeutics

October 29, 2018
·
2 min read
From Cell Therapy, Digitization and Brexit to IPO – Biotech and Pharma Experts Discuss at the European Business Development Conference

More than 120 attendees gathered from the 17th to 18th October in Hannover for the European Business Development Conference (EBDC), the yearly biotech partnering event of the German biotechnology industry association BIO Deutschland.

October 29, 2018
·
4 min read
Business

Abingworth appoints Jackie Grant as Principal

Abingworth today announced that Jackie Grant, PhD, MBA, will join Abingworth as a Principal based in the company’s Boston office. Jackie has more than 10 years of scientific, research and business development experience.

October 29, 2018
·
1 min read
Business

Is the Biotech Bull Market Over?

It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.

October 29, 2018
·
2 min read
·
Karl Thiel
Drug Development

Roche’s Faricimab Shows Long-Term Durability in Macular Degeneration

Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of neovascular (wet) age-related macular degeneration (nAMD).

October 29, 2018
·
3 min read
·
Mark Terry
Deals

Optibiotix launches ProBiotix Health as a separate company, which could lead to an IPO

OptiBiotix Health has named Adam Reynolds as Non-Executive Chairman of its new specialist probiotic subsidiary ProBiotix Health Limited. With 14 commercial deals in just under 18 months and a strong deal pipeline in place ProBiotix is well placed to become a stand-alone company.

October 29, 2018
·
2 min read
Deals

MDxHealth Provides Business Update for the first nine months of 2018

Product and Service revenue up 29% year-on-year

October 29, 2018
·
6 min read
Deals

Takeda’s $80 Billion Acquisition of Shire Hits Snag in Europe

As the acquisition of Shire by Takeda Pharmaceutical inches forward, global regulatory agencies are signing off on the deal. As the European Commission (EC) conducts a review of the deal, it hit a snag.

October 29, 2018
·
3 min read
·
Mark Terry